Skip to Content

Dronabinol Pregnancy and Breastfeeding Warnings

Dronabinol is also known as: Marinol, Syndros

Dronabinol Pregnancy Warnings

Use is recommended only if the potential benefit justifies the potential risk to the fetus. US FDA pregnancy category: Not assigned. Risk summary: Use may result in fetal harm.

Animal studies have not revealed any evidence of teratogenicity. Adverse effects including decreased maternal weight gain and number of viable pups, and increased fetal mortality and early resorptions were dose-dependent and less apparent at lower doses which produced less maternal toxicity. There are no controlled data in human pregnancy. Animal studies also showed some fertility effects including reduced ventral prostate, seminal vesicle, and epididymal weights and decreased seminal fluid volume, spermatogenesis, number of developing germ cells, and number of Leydig cells in the testis. However, no effect has been observed on sperm count, mating success, and testosterone levels. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Dronabinol Breastfeeding Warnings

Use in nursing mothers is not recommended. Excreted into human milk: Yes Comments: -This drug is absorbed by the nursing infant. There are limited data on the effects on the nursing infant. -Patients with nausea and vomiting associated with chemotherapy should avoid breastfeeding for at least 9 days after the last dose.

One long-term study found that daily or near daily marijuana use might delay a breastfed infant's motor development, but not growth or intellectual development. Other studies found that occasional maternal marijuana use during breastfeeding did not have any discernible effects on nursing infants, but these studies were inadequate to rule out all long-term harm.

See references

References for pregnancy information

  1. "Product Information. Marinol (dronabinol)." Roxane Laboratories Inc, Columbus, OH.
  2. "Product Information. Syndros (dronabinol)." Insys Therapeutics Inc, Phoenix, AZ.

References for breastfeeding information

  1. "Product Information. Marinol (dronabinol)." Roxane Laboratories Inc, Columbus, OH.
  2. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  3. "Product Information. Syndros (dronabinol)." Insys Therapeutics Inc, Phoenix, AZ.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.